Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine
Open Access
- 1 April 2020
- journal article
- review article
- Published by Elsevier BV in Vaccine
- Vol. 38 (18), 3489-3500
- https://doi.org/10.1016/j.vaccine.2019.11.058
Abstract
No abstract availableKeywords
Funding Information
- GlaxoSmithKline
This publication has 44 references indexed in Scilit:
- Herpes Zoster Eye Complications: Rates and TrendsMayo Clinic Proceedings, 2013
- Using time‐to‐onset for detecting safety signals in spontaneous reports of adverse events following immunization: a proof of concept studyPharmacoepidemiology and Drug Safety, 2012
- Guillain–Barré syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety dataVaccine, 2011
- The impact of herpes zoster and post-herpetic neuralgia on quality-of-lifeBMC Medicine, 2010
- Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccinesThe Lancet, 2010
- Incidence of Guillain-Barre syndrome in Alberta, Canada: an administrative data studyJournal of Neurology, Neurosurgery & Psychiatry, 2008
- Herpes Zoster Ophthalmicus: Natural History, Risk Factors, Clinical Presentation, and MorbidityOphthalmology, 2008
- Hospital Admissions for Guillain-Barré Syndrome in the United States, 1993–2004Neuroepidemiology, 2007
- Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): Case definitions and guidelines for collection, analysis, and presentation of immunization safety dataVaccine, 2007
- Anaphylaxis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety dataVaccine, 2007